Discovery and characterization of olokizumab: A humanized antibody targeting interleukin-6 and neutralizing gp130-signaling

Interleukin-6 (IL-6) is a critical regulator of the immune system and has been widely implicated in autoimmune disease. Here, we describe the discovery and characterization of olokizumab, a humanized antibody to IL-6. Data from structural biology, cell biology and primate pharmacology demonstrate th...

Descripción completa

Detalles Bibliográficos
Autores principales: Shaw, Stevan, Bourne, Tim, Meier, Chris, Carrington, Bruce, Gelinas, Rich, Henry, Alistair, Popplewell, Andrew, Adams, Ralph, Baker, Terry, Rapecki, Steve, Marshall, Diane, Moore, Adrian, Neale, Helen, Lawson, Alastair
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2014
Materias:
Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4011921/
https://www.ncbi.nlm.nih.gov/pubmed/24670876
http://dx.doi.org/10.4161/mabs.28612
Descripción
Sumario:Interleukin-6 (IL-6) is a critical regulator of the immune system and has been widely implicated in autoimmune disease. Here, we describe the discovery and characterization of olokizumab, a humanized antibody to IL-6. Data from structural biology, cell biology and primate pharmacology demonstrate the therapeutic potential of targeting IL-6 at “Site 3”, blocking the interaction with the signaling co-receptor gp130.

Ejemplares similares